A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

Last updated:
2026-08-01
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BAXDROSTAT IN PARTICIPANTS WITH UNCONTROLLED HYPERTENSION ON TWO OR MORE MEDICATIONS INCLUDING PARTICIPANTS WITH RESISTANT HYPERTENSION

Intervention/treatment:
BAXDROSTAT
Medical condition:
HYPERTENSION
Protocol code:
D6970C00002
Control number:
278294
Status:
Closed
Approved:
September 14, 2023
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06034743
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 130 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Global Clinical Lead
Organization
AstraZeneca
Phone:
1-887-240-9479
Sponsor
ASTRAZENECA CANADA INC

Locations

Alberta

Research Site
Edmonton, Alberta, T6G 2C8

British Columbia

Research Site
North Vancouver, British Columbia, V7M 2H4

Ontario

Research Site
Cambridge, Ontario, N1R 6V6
Research Site
Markham, Ontario, L3S 0A2
Research Site
Newmarket, Ontario, L3Y 2P6
Research Site
Ottawa, Ontario, K1H 7W9
Research Site
Scarborough Village, Ontario, M1B 4Z8
Research Site
Toronto, Ontario, M6G 1M2
Research Site
Waterloo, Ontario, N2T 0C1

Quebec

Research Site
Chicoutimi, Quebec, G7H 7K9
Research Site
Saint-Jean-sur-Richelieu, Quebec, J3A 1J2

Results

See the results from the trial NCT06034743. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?